Work

No Significant Changes to Residual Viremia After Switch to Dolutegravir and Lamivudine in a Randomized Trial

Year: 2019

Type: article

Abstract: In the ASPIRE trial, antiretroviral therapy (ART) switch to dolutegravir plus lamivudine (DTG+3TC) was comparable to 3-drug ART in maintaining viral suppression by standard viral load assays. We used an ultrasensitive assay to assess whether this switch led to increased residual viremia. At entry, levels of residual viremia did not differ significantly between arms (DTG+3TC vs 3-drug ART: mean, 5.0 vs 4.2 HIV-1 RNA copies/mL; P = .64). After randomization, no significant between-group differences were found at either week 24 or 48. These results show no evidence for increased viral replication on DTG+3TC and support its further investigation as a dual ART strategy.

Source: Open Forum Infectious Diseases

DOI: 10.1093/ofid/ofz056

Authors: Jonathan Z Li, Paul E Sax, Vincent C Marconi, Jesse Fajnzylber, Baiba Berzins, Amesika N Nyaku, Carl J Fichtenbaum, Timothy Wilkin, Constance A Benson, Susan L Koletar, Ramon Lorenzo-Redondo, Babafemi O Taiwo

Institutions: Brigham and Women's Hospital, Harvard University, Emory University, Northwestern University, Rutgers, The State University of New Jersey, University of Cincinnati, Weill Cornell Medicine, University of California San Diego, The Ohio State University

Language: English

Topic: HIV/AIDS drug development and treatment

Subfield: Infectious Diseases

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $4,053

Funders: Bristol-Myers Squibb, Pfizer, GlaxoSmithKline, Gilead Sciences, Emory University, Northwestern University, ViiV Healthcare, National Institutes of Health, National Institute of Allergy and Infectious Diseases

Awards: G183157880, G6113675784, G681742546, Center for AIDS Research at Emory University

OpenAlex ID: W2916623820

FWCI: 2.058

Cites: 25

Cited by: 20

Related to: 10